Abstract 514P
Background
Glioblastoma (GBM) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping its tumor microenvironment (TME) regulate tumor initiation, progression, and treatment response. The aim of this study was to characterize the TME and the expression of immunomodulatory targets in patients (pts) with GBM.
Methods
Immunohistochemistry for CD3, CD4, CD8, programed death ligand 1 (PD-L1) and programed death 1 (PD1) was performed on surgical tumor specimens from pts diagnosed with GBM, according to the CNS WHO 2021 criteria. A descriptive statistic was applied to the data set. OS and PFS were estimated through the Kaplan-Meier method and analyzed by the means of a log-rang test.
Results
We included 30 pts, with median age of 59.8 years [range 40.2-69.1 years]. All pts were treated with surgery followed by temozolomide concurrent with and adjuvant to radiotherapy. MGMT was methylated in 46.7% of pts and unmethylated in 53.3% of pts. Overall CD4+ lymphocytes, both intratumoral and perivascular, were significantly more represented than CD8+ lymphocytes in the GBM TME (p= 0.01). A lower density of CD4+ lymphocytes (<10%) was found to be a favorable prognostic factor for GBM outcome (p= 0.02). Pts with MGMT methylated and unmethylated tumors exhibited a distinct TME composition, with a significant higher number of perivascular CD8+ lymphocytes (p= 0.002), intratumoral CD8+ lymphocytes (p= 0.0024) and perivascular CD4+ lymphocytes (p=0.014) in MGMT unmethylated compared to MGMT methylated tumors. PD-L1 expression in GBM cell surface was 13.3% (n=4) and PD1 was expressed in 30% (N=9) of the GBM-infiltrating T cells, with predominantly perivascular distribution.
Conclusions
CD4+ lymphocytes lower density (<10%) correlates with improved survival. Given the small numbers of our cohort, the prognostic value of CD4+ lymphocytes density needs to be validated in large-scale studies. MGMT methylated and unmethylated tumors exhibit different immune profiles, reflecting the different biology of these tumors. The expression of PD-L1 and PD1 in GBM patients is confined to a small subpopulation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09